Skip to content

News

US Preventive Services Task Force: Ovarian Cancer Screening...

US Preventive Services Task Force: Ovarian Cancer Screening Not Effective for Low-Risk Women

(February 14, 2018) Today the US Preventive Task Force updated their recommendation on ovarian cancer screening, reaffirming their 2012 position that screening average risk women for ovarian cancer is not effective in reducing mortality from the disease. Furthermore, they stated that screening for ovarian cancer carries certain risk and harms that may be substantial, and … Continued

Ovarian Cancer Risk and BRCA1 Methylation

Ovarian Cancer Risk and BRCA1 Methylation

(January 31, 2018) A study published in the Annals of Internal Medicine explains that researchers now believe that the methylation of normal BRCA1 gene promotion, not solely BRCA1 mutation, is a risk factor for ovarian cancer. Methylation can be detrimental because it blocks a gene from being transcribed, which means that it can’t repair any … Continued

HIPEC Beneficial in Late Stage Ovarian Cancer

HIPEC Beneficial in Late Stage Ovarian Cancer

(January 29, 2018) A study recently published in the New England Journal of Medicine looked at the difference between two treatment strategies for newly diagnosed stage III epithelial ovarian cancer patients, with the goal of identifying the treatment with a higher rate of recurrence free survival. The first treatment option, typical for advanced stage ovarian … Continued

Can Cancer Be Detected and Located by a Blood Test?

Can Cancer Be Detected and Located by a Blood Test?

(January 25, 2018) CancerSEEK is a blood test designed to detect cancer by analyzing levels of proteins and mutations in cell-free DNA. The goal of this particular blood test is to assist in early detection, and therefore decrease cancer related deaths, for ovarian, liver, stomach, pancreas, esophagus, colorectum, lung, and/or breast cancers. The results of … Continued

OCRFA Awards $5.3 Million in Scientific Research Grants for...

OCRFA Awards $5.3 Million in Scientific Research Grants for 2018

(January 25, 2018) OCRFA has just awarded more than $5.3 million in new scientific research grants for ovarian cancer, bringing our total investment in life-saving research to over $80 million. This year’s grants have been awarded to twenty top scientists at sixteen leading medical centers across the country. “Our 2018 grantees are truly some of … Continued

OCRFA Research Shows Novel Combination Therapy Effective in...

OCRFA Research Shows Novel Combination Therapy Effective in Ovarian Cancer

(December 20, 2017) Cell Reports published new research from the Wistar Institute, which looked at the potential benefits of a therapy that combines PARP inhibitors and BET inhibitors for ovarian cancer patients without BRCA mutations. The research was funded in part by an OCRFA grant to Rugang, Zhang, PhD. PARP inhibitors have already been approved … Continued

OCRFA’s Impact in 2017

OCRFA’s Impact in 2017

(December 14, 2017) For over two decades, you have made it possible for OCRFA to fund the most innovative and promising science, resulting in research breakthroughs that have advanced our understanding of ovarian cancer, how it starts and new treatment options, and you have enabled OCRFA to successfully advocate for federal research dollars and provide … Continued

The Relationship Between Cytotoxic CD8 Tumor-Infiltrating L...

The Relationship Between Cytotoxic CD8 Tumor-Infiltrating Lymphocytes and Overall Survival in High Grade Serous Ovarian Cancer

(December 11, 2017) A study by the Ovarian Tumor Tissue Analysis Consortium, published in JAMA Oncology, looked at the association between cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) and overall survival with certain types of ovarian cancer. After an immunohistochemical analysis of 5,577 patients, researchers saw a strong correlation between high levels of CD8+ TILs and longer … Continued

Study Reveals Overall Survival Disparities Among Race and S...

Study Reveals Overall Survival Disparities Among Race and Stage

(December 8, 2017) The results of the CONCORD-2 study, recently published in Cancer, show a large difference in ovarian cancer survival between black women and white women, and also between stages at diagnosis. The data collected from the study, the largest of its kind, looked at 172,849 cases of ovarian cancer, over the course of … Continued

Phase II Trial Points to Possible Benefits of IP Chemothera...

Phase II Trial Points to Possible Benefits of IP Chemotherapy after Neoadjuvant Therapy and Surgery

(December 4, 2017) The results of a phase II trial, which focused on stages IIB to IVA epithelial ovarian cancer, were recently published in the Annals of Oncology. The primary purpose of the six year, two stage, multicenter trial was to look at the nine month progressive disease rate when using intraperitoneal (IP) chemotherapy after … Continued

OCRFA Funded Research Identifies Mechanism Underlying Ovari...

OCRFA Funded Research Identifies Mechanism Underlying Ovarian Cancer Development

(November 22, 2017) A recent paper published in the Journal of Clinical Investigation reports that a subset of ovarian cancers reduce the expression of a critical gene involved in recycling the cells’ proteins, known as ubiquitin B (UBB). Silencing the expression of a closely related gene, also in the ubiquitin family, that performs an identical … Continued

New Research Indicates that High Grade Serous Ovarian Carci...

New Research Indicates that High Grade Serous Ovarian Carcinomas Originate in the Fallopian Tubes

(October 30, 2017) Until recently, it was thought that high-grade serous ovarian carcinomas (HGSOCs) arose from the ovarian surface epithelium, but recent data from two studies published in Nature Communications suggest that all high grade serous ovarian cancers do in fact originate in the fallopian tube. These findings have implications for ovarian cancer detection and … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.